Empowered Funds LLC Acquires Shares of 23,220 Becton, Dickinson and Company $BDX

Empowered Funds LLC acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 23,220 shares of the medical instruments supplier’s stock, valued at approximately $3,514,000.

A number of other institutional investors also recently made changes to their positions in the business. Larson Financial Group LLC grew its position in shares of Becton, Dickinson and Company by 1.7% during the fourth quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock worth $627,000 after buying an additional 53 shares in the last quarter. Atlantic Union Bankshares Corp raised its holdings in Becton, Dickinson and Company by 0.9% in the fourth quarter. Atlantic Union Bankshares Corp now owns 6,108 shares of the medical instruments supplier’s stock valued at $1,185,000 after acquiring an additional 57 shares in the last quarter. Elevation Point Wealth Partners LLC raised its holdings in Becton, Dickinson and Company by 3.7% in the second quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier’s stock valued at $256,000 after acquiring an additional 60 shares in the last quarter. BOK Financial Private Wealth Inc. boosted its stake in Becton, Dickinson and Company by 7.3% during the 2nd quarter. BOK Financial Private Wealth Inc. now owns 1,073 shares of the medical instruments supplier’s stock valued at $162,000 after acquiring an additional 73 shares during the last quarter. Finally, Keating Financial Advisory Services Inc. grew its holdings in Becton, Dickinson and Company by 41.6% during the 2nd quarter. Keating Financial Advisory Services Inc. now owns 252 shares of the medical instruments supplier’s stock worth $38,000 after acquiring an additional 74 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Down 0.5%

NYSE:BDX opened at $187.23 on Wednesday. The stock has a market cap of $51.59 billion, a price-to-earnings ratio of 56.39, a PEG ratio of 13.26 and a beta of 0.21. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $193.07. The business has a fifty day moving average of $167.95 and a 200-day moving average of $160.37.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. The business had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company’s revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the business earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is 126.51%.

Analyst Ratings Changes

Several equities analysts have recently commented on BDX shares. Piper Sandler increased their price target on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Wells Fargo & Company lifted their target price on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. TD Cowen boosted their price target on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Finally, Evercore set a $180.00 target price on Becton, Dickinson and Company in a research note on Monday, July 6th. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $187.67.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the sale, the executive vice president owned 13,172 shares of the company’s stock, valued at $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the sale, the executive vice president owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 9,105 shares of company stock valued at $1,590,208. 0.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.